Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Roberto Esquivel-García has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Adverse events and potential herb-drug interactions of plants used for psoriasis: A systematic review

    by Marwan Gagaa, Roberto Esquivel-García, María E. Velázquez-Hernández, Isis B. Bermúdez-Camps, Manuel García-Pérez, Alain R. Rodríguez-Orozco, Ivette Reyes-Hernández, Martha E. García-Pérez

    Context: Medicinal plants have been widely used for psoriasis management for centuries. However, their safety profiles remain insufficiently documented. Aims: To systematically evaluate adverse events (AEs) and potential pharmacokinetic interactions of antipsoriatic herbal treatments. Methods: A PRISMA-compliant review was conducted using PubMed, Cochrane, Google Scholar, Web of Science, and Scopus databases (January 2015-December 2022). Clinical trials, case reports, and ethnomedicinal studies reporting AEs of single plant antipsoriatic preparations were included. CONSORT criteria for herbal medicines were applied to assess study quality. Results: Eleven studies covering nine herbal treatments were included. While most of reported AEs were mild, severe cases involving Indigo naturalis, Psoralea corylifolia, and Ranunculus arvensis were documented. Several herbal metabolites (indirubin, psoralen, curcumin, triptolide) showed potential pharmacokinetic interactions with conventional drugs. Conclusions: While generally well tolerated, antipsoriatic herbal therapies can induce mild to severe AEs and may alter drug metabolism. Long-term, high-quality randomized trials are needed to establish their safety profile.

  • Open Access

    Cuachalalate (Amphipterygium adstringens): un viaje desde la medicina ancestral hasta la actualidad

    by Miriam Lizbeth Bautista Aguilar, Martha Estrella García Pérez, Roberto Esquivel García

    En el contexto de la medicina tradicional y la investigación científica, las plantas medicinales desempeñan un papel crucial, reflejando la riqueza del conocimiento ancestral. El cuachalalate (Amphipterygium adstringens), es una especie endémica de México, que ha sido ampliamente aprovechada desde épocas prehispánicas, destacando su uso medicinal y su aplicación artesanal. Reconocido por sus propiedades adstringentes, cicatrizantes, antibióticas, antimaláricas y antiinflamatorias es una especie fascinante que nos lleva de la mano desde los tiempos antiguos hasta las modernas tendencias farmacológicas. Acompáñanos a descubrirlo.


  • Ethanolic extract, solvent fractions, and bio-oils from Urtica subincisa: Chemical composition, toxicity, and anti-IL-17 activity on HaCaT keratinocytes

    by Roberto Esquivel-García, Ayca Seker, Nehal I. Abu-Lail, Manuel García-Pérez, Alejandra Ochoa-Zarzosa, Martha-Estrella García-Pérez


  • Updated view of tars for psoriasis: what have we learned over the last decade?

    by Miguel Ávalos‐Viveros, Roberto Esquivel‐García, Enelio Torres‐García, María‐Carmen Bartolomé‐Camacho, Víctor Santes, Martha‐Estrella García‐Pérez

    Tars are one of the most effective, unknown, and oldest therapies for psoriasis. They include coal tar (CT) and biomass‐derived products. These treatments, particularly the CT, have proven to be cost‐effective with long remission times compared to other systemic or topical treatments. However, they have hardly evolved in recent years, as they are not well‐embraced by clinicians or patients because of concerns regarding cosmesis and safety. This review summarizes current knowledge about the chemical characterization, mechanism of action, toxicity, and clinical studies supporting the use of tars for psoriasis over the last decade. Trends within these above aspects are reviewed, and avenues of research are identified. CT is rich in polycyclic aromatic hydrocarbons, whereas biomass‐derived tars are rich in phenols. While the activation of the aryl hydrocarbon receptor is involved in the antipsoriatic effect of CT, the mechanism of action of biomass‐derived products remains to be elucidated. No conclusive evidence exists about the risk of cancer in psoriasis patients under CT treatment. Large, randomized, double‐blind, controlled clinical trials are necessary to promote the inclusion of tars as part of modern therapies for psoriasis.


  • Pyrolytic oils from Amphipterygium adstringens bark inhibit IL-8 production of IL-17-stimulated HaCaT keratinocytes

    by Roberto Esquivel-García, Michael Ayiania, Nehal Abu-Lail, Joel E. López-Meza, Rosa E. del Río, Manuel García-Pérez, Alejandra Ochoa-Zarzosa, Martha-Estrella García-Pérez


  • Open Access

    Ethnomedicinal plants used for the treatment of dermatological affections on the Purépecha Plateau, Michoacán, Mexico

    by Roberto Esquivel-García, Emmanuel Pérez-Calix, Alejandra Ochoa-Zarzosa, Martha Estrella García-Pérez

    Background and Aims: Inhabitants of the Purépecha Plateau preserve an excellent ancestral knowledge on medicinal plants used for dermatological affections, which has not been documented. An ethnopharmacological survey was carried out in this region to gather information on the use of medicinal plants and herbal preparations for treating dermatological affections, to disseminate the Purépecha indigenous knowledge and identifying promising plants for developing new formulations for cutaneous conditions.Methods: The study was conducted in the 21 municipalities that compose the Purépecha Plateau. A total of 86 local inhabitants (62 women and 24 men) were interviewed. The data were quantitatively analyzed through the determination of the use value, fidelity level and informant consensus factor.Key results: A total of 97 plant species belonging to 47 families were documented for treating 19 dermatological conditions on the Purépecha Plateau. Asteraceae was the leading family among the collected medicinal plants (20.61%), followed by Lamiaceae (13.40%) and Solanaceae (5.15%). The largest number of plants was used for the treatment of cuts (40.20%), skin inflammation (37.11%) and rash (37.11%). The aerial parts were the most commonly used (34.75%). The medicinal plant species with larger use values were Heterotheca inuloides (0.53), Aloe vera (0.37) and Oenothera rosea (0.21). The comparison of results with ethnomedicinal literature worldwide revealed that 8.25% of plants used on the Purépecha Plateau were recorded for the first time for the treatment of dermatological affections.Conclusions: This study provides new information on medicinal plants used on the Purépecha Plateau to treat cutaneous diseases. Future pharmacological and toxicological investigations are required to demonstrate the efficacy and safety of these species for treating dermatological affections.


  • La psoriasis: de la investigación básica y clínica al desarrollo de nuevos tratamientos

    by Roberto Esquivel-García, Gabino Estévez-Delgado, Alain Raimundo Rodríguez-Orozco, Alejandra Ochoa-Zarzosa, Martha Estrella García-Pérez

    Psoriasis is an incurable cutaneous disease that affects 2.9% of the Mexican population, and it is therefore important for the impact of translational medicine on the development of anti-psoriatic drugs to be analyzed. In this review, current etiopathogenic concepts of the disease are discussed, and articles on drugs under development published between 2005 and 2017 are reviewed; in addition, a critical analysis on future perspectives for the development new treatments is presented. The use of translational medicine bi-directional strategies of has allowed to significantly increase the number of available anti-psoriatic therapies. Eighteen new investigational drugs were found. Characterization of antigens responsible for immune activation, identification of predictive biomarkers with pharmacologic efficacy, and the development of more representative disease models, as well as the integration of pharmacogenomic aspects to translational medicine strategies were identified as relevant aspects that should be incorporated in the development of new therapeutic options.